Answer to Mungmunpuntipantip et al. "SARS CoV-2 vaccine AND rituximab" Joint Bone Spine 2021;88:105281.
作者信息
Verhoeven Frank, Lepiller Quentin, Hecquet Sophie, Prati Clément, Wendling Daniel
机构信息
Department of Rheumatology, CHRU de Besançon, 3, boulevard Fleming, 25000 Besançon, France; EA 4267 "PEPITE", UFR Santé, Franche-Comté University, 19, rue Ambroise Paré, bâtiment S, 25030 Besançon cedex, France.
Virology laboratory, CHRU de Besançon, 3, boulevard Fleming, 25000 Besançon, France.
出版信息
Joint Bone Spine. 2022 Jan;89(1):105283. doi: 10.1016/j.jbspin.2021.105283. Epub 2021 Oct 1.
Abstract
摘要
相似文献
1
Answer to Mungmunpuntipantip et al. "SARS CoV-2 vaccine AND rituximab" Joint Bone Spine 2021;88:105281.对蒙蒙蓬蒂潘蒂普等人《严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗》的回复，《关节与脊柱》2021年；88:105281
Joint Bone Spine. 2022 Jan;89(1):105283. doi: 10.1016/j.jbspin.2021.105283. Epub 2021 Oct 1.
2
SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗。评论：Verhoeven等人在《关节与脊柱》杂志上发表的“严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗，时机可能是获得更好疫苗反应的关键”。2021年；88:105258 。
Joint Bone Spine. 2022 Jan;89(1):105281. doi: 10.1016/j.jbspin.2021.105281. Epub 2021 Sep 29.
3
Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven et al. Joint Bone Spine 2021;88:105258.对Verhoeven等人所著《SARS-CoV-2疫苗与利妥昔单抗，时机可能是获得更好疫苗反应的关键》的评论。《关节与脊柱》2021年；88:105258 。
Joint Bone Spine. 2022 Oct;89(5):105408. doi: 10.1016/j.jbspin.2022.105408. Epub 2022 May 13.
4
SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response.严重急性呼吸综合征冠状病毒2型疫苗与利妥昔单抗，接种时机可能是获得更好疫苗反应的关键。
Joint Bone Spine. 2021 Dec;88(6):105258. doi: 10.1016/j.jbspin.2021.105258. Epub 2021 Sep 2.
5
Answer to Cadiou et al. "SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger?". Joint Bone Spine 2021;88:105282.对卡迪乌等人《严重急性呼吸综合征冠状病毒2型、风湿性多肌痛和巨细胞动脉炎：新冠疫苗接种是诱因吗？》的回复。《关节与脊柱》2021年；88:105282
Joint Bone Spine. 2022 Jan;89(1):105284. doi: 10.1016/j.jbspin.2021.105284. Epub 2021 Oct 1.
6
Answer to Cabona et al « Isolated musculocutaneous nerve involvement in COVID-19 related Neuralgic amyotrophy» Joint Bone Spine 2021;88:105238 and to Finsterer and Scorza « SARS-CoV-2 or SARS-CoV-2 vaccination associated Parsonage-Turner syndrome». Joint Bone Spine 2021;88:105239.对卡博纳等人《新型冠状病毒肺炎相关神经痛性肌萎缩中孤立性肌皮神经受累》（《关节与脊柱》2021年；88卷：105238）以及对芬斯特勒和斯科尔扎《严重急性呼吸综合征冠状病毒2或严重急性呼吸综合征冠状病毒2疫苗接种相关的帕森热-特纳综合征》（《关节与脊柱》2021年；88卷：105239）的回应。
Joint Bone Spine. 2021 Dec;88(6):105240. doi: 10.1016/j.jbspin.2021.105240. Epub 2021 Jun 17.
7
SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: "Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?" by Manzo et al. Joint Bone Spine 2021;88:105150.严重急性呼吸综合征冠状病毒2、风湿性多肌痛和巨细胞动脉炎：新冠疫苗接种会成为诱因吗？对曼佐等人所著《严重急性呼吸综合征冠状病毒2会引发风湿性多肌痛复发吗？》的评论。《关节与脊柱》2021年；88:105150
Joint Bone Spine. 2022 Jan;89(1):105282. doi: 10.1016/j.jbspin.2021.105282. Epub 2021 Sep 29.
8
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli .关于博内利所著的《利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫可诱导的证据》的通信
Ann Rheum Dis. 2021 Oct;80(10):e165. doi: 10.1136/annrheumdis-2021-220957. Epub 2021 Aug 2.
9
Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff .对韦斯托夫的《关于“利妥昔单抗治疗患者的SARS-CoV-2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信》的回复
Ann Rheum Dis. 2021 Oct;80(10):e163. doi: 10.1136/annrheumdis-2021-220764. Epub 2021 Jul 16.
10
Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli .对博内利的《利妥昔单抗治疗患者的SARS-CoV-2疫苗接种：体液免疫受损但细胞免疫可诱导的证据》的通信回复 。
Ann Rheum Dis. 2021 Oct;80(10):e167. doi: 10.1136/annrheumdis-2021-220997. Epub 2021 Aug 2.
Zotero 插件